Capecitabine plus bevacizumab (Cape-Bev) as a maintenance treatment after induction treatment with FOLFIRI plus bevacizumab (FOLFIRI-Bev) in metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Tatli, Ali Murat
Coskun, Hasan Senol
Uysal, Mukremin
Goksu, Sema Sezgin
Arslan, Deniz
Gunduz, Seyda
Ozdogan, Mustafa
Bozcuk, Hakan Sat
Savas, Burhan
机构：
[1] Akdeniz Univ, Fac Med, Dept Med Oncol, TR-07058 Antalya, Turkey
[2] Afyon Kocatepe Univ, Dept Med Oncol, Fac Med, Afyon, Turkey
[3] Medstar Antalya Hosp, Antalya, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14683
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Treatment with capecitabine plus bevacizumab following induction treatment with FOLFIRI plus bevacizumab in metastatic colorectal carcinoma
    Tatli, Ali Murat
    Coskun, Hasan Senol
    Uysal, Mukremin
    Arslan, Deniz
    Goksu, Sema Sezgin
    Gunduz, Seyda Guenay
    Cakal, Selda
    Bozcuk, Hakan Sat
    Savas, Burhan
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 7 (08): : 2191 - 2196
  • [2] ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.
    Wainberg, Zev A.
    Wang, Lan
    Yue, Huibin
    Motwani, Monica
    Kasichayanula, Sreeneeranj
    Blaney, Martha Elizabeth
    Naumovski, Louie
    Strickler, John H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [4] CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC).
    Ziras, N.
    Polyzos, A.
    Xenidis, N.
    Kalykaki, A.
    Androulakis, N. E.
    Papakotoulas, P.
    Kentepozidis, N. K.
    Makrantonakis, P.
    Xynogalos, S.
    Sougklakos, I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J. C.
    Tournigand, C.
    Bednarczyk, M.
    Swieboda-Sadlej, A.
    Chung, I.
    Barone, C.
    Tarazi, J. C.
    Rosbrook, B.
    Ricart, A. D.
    Sobrero, A. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [6] Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110/ML22011 randomized, phase III trial
    Giessen, Clemens Albrecht
    Modest, Dominik Paul
    Stintzing, Sebastian
    von Weikersthal, Ludwig Fischer
    Vehling-Kaiser, Ursula
    Spaeth-Schwalbe, Ernst
    Freiberg-Richter, Jens
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Peuser, Bettina
    Heinemann, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Giessen, Clemens
    von Weikersthal, Ludwig Fischer
    Hinke, Axel
    Stintzing, Sebastian
    Kullmann, Frank
    Vehling-Kaiser, Ursula
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Freiberg-Richter, Jens
    Schulz, Christoph
    Modest, Dominik Paul
    Moosmann, Nicolas
    Aubele, Philipp
    Heinemann, Volker
    [J]. BMC CANCER, 2011, 11
  • [8] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.
    Cremolini, Chiara
    Loupakis, Fotios
    Masi, Gianluca
    Zagonel, Vittorina
    Bergamo, Francesca
    Salvatore, Lisa
    Cortesi, Enrico
    Tomasello, Gianluca
    Ronzoni, Monica
    Pinta, Francesco
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Amoroso, Domenico
    Sonaglio, Claudia
    De Stefano, Alfonso
    Boni, Corrado
    Allegrini, Giacomo
    Boni, Luca
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [9] A cost-effectiveness analysis of pretreatment DPYD and UGT1A1 screening in patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI plus bevacizumab (FOLFIRI plus Bev)
    Rivers, Zachary
    Stenehjem, David D.
    Jacobson, Pamala
    Lou, Emil
    Nelson, Andrew
    Kuntz, Karen M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Clemens Giessen
    Ludwig Fischer von Weikersthal
    Axel Hinke
    Sebastian Stintzing
    Frank Kullmann
    Ursula Vehling-Kaiser
    Julia Mayerle
    Markus Bangerter
    Claudio Denzlinger
    Markus Sieber
    Christian Teschendorf
    Jens Freiberg-Richter
    Christoph Schulz
    Dominik Paul Modest
    Nicolas Moosmann
    Philipp Aubele
    Volker Heinemann
    [J]. BMC Cancer, 11
12345